货号 (SKU)

包装规格

是否现货

价格

数量

Ab175662-100μg

100μg

现货

Ab175662-1mg

1mg

现货

Ab175662-5mg

5mg

现货

Ab175662-10mg

10mg

期货

基本信息

产品名称	Sugemalimab (anti-PD-L1), 程序性细胞死亡 1 配体的结合剂 1 结合剂
别名	舒格利单抗 \| 舒马利单抗(抗 PD-L1)
英文别名	B7 H antibody \| B7 H1 antibody \| B7 homolog 1 antibody \| B7-H1 antibody \| B7H antibody \| B7H1 antibody \| CD 274 antibody \| CD-274 antibody \| CD274 antibody \| CD274 antigen antibody \| CD274 molecule antibody \| MGC142294 antibody \| MGC142296 antibody \| OTTH
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	CD274
种属反应性	人(Human)
偶联	Unconjugated
作用类型	结合剂
作用机制	程序性细胞死亡 1 配体的结合剂 1 结合剂

产品属性

克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG4SP
轻链亚型	lambda
SDS-PAGE	27.2 kDa (Light Chain) & 51.2 kDa (Heavy Chain), under reducing conditions; 183.8 kDa, under non-reducing conditions.
纯化方法	Protein A purified
纯度	>95%
物理外观	Liquid
储存缓冲液	Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	2256084-03-2
分子类型	抗体

关联靶点（人）

CD274 Tclin 程序性细胞死亡 1 配体 1(Programmed cell death 1 ligand 1) (0 活性数据)

点击查看靶蛋白信息： CD274

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

图片

Flow Cytometry: Sugemalimab (anti-PD-L1) (Ab175662)

Sugemalimab (anti-PD-L1) (Ab175662) - Flow Cytometry
Flow Cytometry analysis of 500 ng/mL Ionomycin (I139530) and 10 ng/mL PMA (P408905) co-stimulated Jurkat cells (24h) labelling PD-L1 (red) with Sugemalimab (anti-PD-L1) (Ab175662). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

SEC: Sugemalimab (anti-PD-L1) (Ab175662)

Sugemalimab (anti-PD-L1) (Ab175662) - SEC
The purity of Sugemalimab (anti-PD-L1) (Ab175662) is more than 95% verified by HPLC.

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到6个结果

批号(Lot Number)	证书类型	货号
ZJ24F1114544	分析证书	Ab175662
ZJ24F1114543	分析证书	Ab175662
ZJ24F1114542	分析证书	Ab175662
ZJ24F0404392	分析证书	Ab175662
ZJ24F0404391	分析证书	Ab175662
ZJ24F0404390	分析证书	Ab175662

可替换产品

引用文献

1. Dhillon S, Duggan S. (2022) Sugemalimab: First Approval.. Drugs, 82 (5): (593-599). [PMID:35298827]
2. Gong J, Cao J, Zhang Q, Xu N, Zhao Y, Xing B, Miao Z, Wu Y, Pan H, Gao Q et al.. (2022) Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial.. Cancer Immunol Immunother, 71 (8): (1897-1908). [PMID:34984540]
3. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS et al.. (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.. N Engl J Med, 369 (2): (134-44). [PMID:23724846]
4. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC et al.. (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.. J Exp Med, 192 (7): (1027-34). [PMID:11015443]
5. Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, Ryu SE, Shin W, Heo YS. (2017) Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.. Sci Rep, 7 (1): (5532). [PMID:28717238]
6. Lin DY, Tanaka Y, Iwasaki M, Gittis AG, Su HP, Mikami B, Okazaki T, Honjo T, Minato N, Garboczi DN. (2008) The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors.. Proc Natl Acad Sci USA, 105 (8): (3011-6). [PMID:18287011]
7. Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, Dömling A, Dubin G, Holak TA. (2015) Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.. Structure, 23 (12): (2341-2348). [PMID:26602187]
8. Cheng B, Ren Y, Niu X, Wang W, Wang S, Tu Y, Liu S, Wang J, Yang D, Liao G, Chen J.. (2020) Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents.. J Med Chem, 63 (15): (8338-8358). [PMID:32667799] [10.1021/acs.jmedchem.0c00574]
9. He, Xian-hui XH, Xu, Li-hui LH and Liu, Yi Y.. (2005) Identification of a novel splice variant of human PD-L1 mRNA encoding an isoform-lacking Igv-like domain.. Acta pharmacologica Sinica, [PMID:15780196]
10. Rosenberg, Jonathan E JE and 30 more authors.. (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.. Lancet (London, England), (7): [PMID:26952546]
11. Kataoka, Keisuke K and 43 more authors.. (2016) Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.. Nature, (16): [PMID:27281199]
12. and Markham, Anthony A.. (2016) Atezolizumab: First Global Approval.. Drugs, [PMID:27412122]
13. Bellmunt, Joaquin J, Powles, Thomas T and Vogelzang, Nicholas J NJ.. (2017) A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.. Cancer treatment reviews, [PMID:28214651]
14. Mezzadra, Riccardo R and 18 more authors.. (2017) Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.. Nature, (7): [PMID:28813410]
15. Burr, Marian L ML and 23 more authors.. (2017) CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.. Nature, (7): [PMID:28813417]
16. Faiena, Izak I and 5 more authors.. (2018) Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.. Drug design, development and therapy, [PMID:29416316]
17. Dong, H H, Zhu, G G, Tamada, K K and Chen, L L.. (1999) B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.. Nature medicine, [PMID:10581077]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

Sugemalimab (anti-PD-L1), 程序性细胞死亡 1 配体的结合剂 1 结合剂

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

关联靶点（人）

作用机制

图片

质检证书（CoA,COO,BSE/TSE 和分析图谱)

可替换产品

引用文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器

Sugemalimab (anti-PD-L1), 程序性细胞死亡 1 配体的结合剂 1 结合剂

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

关联靶点（人）

作用机制

图片

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

可替换产品

引用文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器